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ABSTRACT
The temperature-independent effects of electromagnetic fields (EMF) have been controversial for deca-
des. Here, we critically analyze the available literature on non-thermal effects of radiofrequency (RF)
and microwave EMF. We present a literature review of preclinical and clinical data on non-thermal
antiproliferative effects of various EMF applications, including conventional RF hyperthermia (HT, cRF-
HT). Further, we suggest and evaluate plausible biophysical and electrophysiological models to
decipher non-thermal antiproliferative membrane effects. Available preclinical and clinical data provide
sufficient evidence for the existence of non-thermal antiproliferative effects of exposure to cRF-HT, and
in particular, amplitude modulated (AM)-RF-HT. In our model, transmembrane ion channels function
like RF rectifiers and low-pass filters. cRF-HT induces ion fluxes and AM-RF-HT additionally promotes
membrane vibrations at specific resonance frequencies, which explains the non-thermal antiprolifera-
tive membrane effects via ion disequilibrium (especially of Ca2þ) and/or resonances causing mem-
brane depolarization, the opening of certain (especially Ca2þ) channels, or even hole formation. AM-
RF-HT may be tumor-specific owing to cancer-specific ion channels and because, with increasing
malignancy, membrane elasticity parameters may differ from that in normal tissues. Published litera-
ture suggests that non-thermal antiproliferative effects of cRF-HT are likely to exist and could present
a high potential to improve future treatments in oncology.
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Conventional radiofrequency (RF) hyperthermia (HT, cRF-HT)
or microwave (MW) HT has been evaluated in clinical studies
[1] and is used in the treatment of soft tissue sarcoma in
combination with neoadjuvant chemotherapy [2], and for the
treatment of cervical cancer [3–5] and superficial tumors
[6–9], when combined with radiation therapy (RT). Annular
phased array (APA) systems, capacitive systems (CS), and
local RF or MW applicators are common technologies to
achieve a specific absorption rate (SAR) of 10–60W/kg in the
target region and intended temperatures of 42 C [10,11].
Current knowledge about cRF/MW-HT is based on numerous
preclinical in vitro and in vivo studies mainly using water
bath (WB) HT [12–17]. Generally, WB-HT kills tumor cells at
temperatures 43 C, but a combination of WB-HT with RT
and/or chemotherapy might show efficacy at lower tempera-
tures. Overgaard [14] described a relevant sensitization at
41.5 C [thermal enhancement ratio (TER) of 1.34] if RT and
HT are simultaneously applied. For sequential treatments
however, nearly no cytotoxic effect was observed for temper-
atures 41 C [17]. Thus, preclinical studies predict that
temperatures above 41 C are required for cRF/MW-HT to
enhance the RT effects.
However, these requirements have not been usually
achieved in all parts of the target for patients with deep-
seated tumors (e.g., cervical cancer) in successful randomized
studies investigating cRF-HT [4,5,18–21]. A conspicuous
inconsistency between preclinical and clinical data remains
as clinical trials using cRF-HT have demonstrated positive
results. Improved reoxygenation and higher heat sensitivity
of hypoxic (radioresistant) cells have been used to explain
the favorable clinical results. Likewise, extreme whole body
HT [22], a non-RF-based clinical counterpart of water bath
HT, has resulted in disappointing clinical results even though
the basic requirements, i.e., covering the target at tempera-
tures >41.5 C are always fulfilled.
Recently, a couple of clinical studies provided evidences
of non-thermal effects in human tumors using AM-RF or RF.
The researchers applied clinical systems like mEHT (modu-
lated electro-hyperthermia [23,24], TTF (tumor treating fields)
[25] and the TheraBionic device [26,27]. These studies have
in common according to the general understanding of
hyperthermia that temperature increases are below 40 C
and the observed effects are to be regarded as non-thermal.
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Therefore, we hypothesize that additional non-thermal
effects of the electromagnetic fields (EMF) exist and are clin-
ically validated. This hypothesis is controversial as it chal-
lenges current textbook knowledge and has a high potential
to impact clinical practice. Thus, we summarize the current
information regarding the non-thermal effects of EMF.
2. Methods
We found an unmanageable number of hits in Google
Scholar when we were searching for non-thermal biological
effects of electromagnetic fields, such as 25,900 hits for the
search term “non-thermal biological effects of electromag-
netic fields” or even 1,900,000 hits for “electromagnetic field
effects on cells”. For the hyperthermia community, we
assessed three clinical approaches (mEHT, TheraBionic and
TTF) of maximum interest. Current studies with these
approaches have been carefully analyzed to determine
whether they provide evidence of non-thermal effects
(Section 3). They were considered if they were either
randomized or they used the EMF application alone. Hence,
we discarded clinical phase I/II studies if EMF was used in
combination with any other potentially effective schedule, as
such studies might have a strong selection bias, making the
clinical outcomes non-evaluable.
Then we took into account all publications that provided
preclinical and methodological information for these clinical
approaches. That is a considerable but manageable amount
of work (Section 4).
In both sections, for clinical and preclinical studies the
thermometry is crucial to differentiate between thermal and
non-thermal effects. We evaluated not only the accuracy of
the temperature measurements in selected points but also
analyzed the setup in order to estimate the spatial tempera-
ture distribution. In particular, we had to discuss (and to
exclude) unrecognized hot spots that are most frequently
brought up in the field in order to refute non-thermal
effects. If temperature measurements were missing, we
attempted a reliable estimation of the temperature from the
applied power and resulting SAR (specific absorption rate)
distribution.
It is a frequent objection to the existence of non-thermal
effects that no convincing physical explanations have been
found so far. Thus, the presentation of biophysical and elec-
trophysiological models, which are able to explain such
effects, is a central part of this work (Section 5). We empha-
size that such a theoretical framework is novel but is
deduced from a still incomplete database. Verification or
even establishment of a final theory about membrane effects
of EMF was neither intended nor possible.
3. Clinical studies
Regional cRF-HT can reach intermediate temperatures of
39–43 C in larger areas and is suitable for extended cancer
diseases. Typically, total powers of >500W are applied using
the most advanced APA systems. The gained temperatures
are nevertheless not sufficient, since T90, i.e., the temperature
exceeded in 90% of the tumor, is below 40 C [4,18].
In the following, we report on three clinical approaches
(mEHT, TTF and TheraBionic), which unequivocally demon-
strate in our understanding that non-thermal effects should
exist. No or incomplete thermometry was performed in the
outlined studies. Clinically experienced users of hyperthermia
know, however, that with the low power levels applied (as
listed below), temperatures high enough for any relevant
thermal effect could never be reached.
3.1. Clinical application of AM-RF-HT at 13.56MHz
Szasz et al. [28] provided a summary of the clinical evidence
for use of AM-RF-HT, also referred to as mEHT. However, only
a few clinical reports are suitable for evaluating the effect
and significance of AM-RF-HT. Most notably and very
instructive is a randomized study applying AM-RF-HT against
cervical cancer [23]. The authors used the AM-RF-HT system,
which is basically, a CS, and applied a remarkably low total
power of 130W without conducting any temperature meas-
urement. Lee et al. [29,30] conducted a study on recurrent
cervical cancer, utilizing AM-RF-HT with even slightly higher
power of 150W and measured temperatures in and around
the cervical tumor, recording a mean temperature of 38.5 C
(38–40 C). Thus, we estimate similar or even lower tumor
temperatures in the above study that are not efficient in the
sense of conventional hyperthermia.
Minnaar et al. achieved enhanced radiochemotherapy effi-
cacy by the inclusion of AM-RF-HT, resulting in minimal cost
and effort (low resource setting) without increased toxicity.
An additional analysis revealed that effective AM-RF-HT could
be employed nearly independently of the body mass index
with negligible toxicity [24]. Interestingly, FDG-PET revealed
that the majority of patients manifested extrapelvic (mostly
para-aortic) lymph node disease (70%) and were included
in the study, while the RT and AM-RF-HT fields were confined
to the pelvis. In these patients, complete metabolic remission
was significantly more frequent than that in the AM-RF-HT-
group (24.1% vs. 5.6%), suggesting an abscopal effect. These
clinical observations are consistent with preclinical studies
outlined in the next Section 4.
In comparison, other positive randomized trials on cervical
cancer and cRF-HT required significantly higher total power
either utilizing the elaborate APA technology with a total
power of 400–800W [3,18] or capacitive technology without
AM with a total power of 800–1500W [4,5]. Recently, an
extensive update of heating technology for cRF-HT has been
provided [11].
Furthermore, three retrospective reports are of interest in
the assessment of the potential of AM-RF-HT. Lee et al.
[29,30] treated patients with pre-irradiated cervical cancer
recurrences either with chemotherapy alone (n¼ 20, plat-
inum-based with paclitaxel or 5-FU) or chemotherapy plus
AM-RF-HT for 60min three times each week for a total of 36
sessions in 12weeks (n¼ 18). The last follow-up demon-
strated a significantly improved response in the AM-RF-HT-
group [50% complete response (CR), 10% partial response
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(PR), 10% stable disease (SD), 30% progressive disease (PD)
versus 15% CR, 15% PR, 5% SD, 65% PD, p¼ 0.0218]. Both
groups were well balanced according to age, FIGO stage,
pathology, and recurrent lesions.
Fiorentini et al. [31] applied AM-RF-HT monotherapy to 28
patients with recurrent glioblastoma multiforme (GBM) and
22 patients with recurrent anaplastic astrocytoma (AST) who
relapsed after standard first-line treatments (surgery, adju-
vant radiochemotherapy and TMZ) [32]. The remaining
patients in this retrospective observational multicenter
cohort-controlled study (83 GBM, 14 AST) received best sup-
portive care (BSC), including dexamethasone and palliative
chemotherapy in 28 patients with GBM. Tumor response
after 3months (CRþ PRþ SD) was significantly higher in the
AM-RF-HT group, i.e., 72% (AST) and 54% (GBM) vs. 37%
(AST) and 19% (GBM) in the BSC group. Even if we consider
a selection bias in favor of patients with AM-RF-HT, we must
consider 10/22 objective responses (2 CR and 8 PR) in the
AM-RF-HT group with AST (41%) and 7/28 objective
responses (1 CR and 6 PR) in the AM-RF-HT group with GBM
(25%). Apparently, a mean of 22 (range 11–62) AM-RF-HT
sessions alone (150W for 60min after a step-up power
protocol) can bring about relevant tumor regression.
Questions remain due to the retrospective nature of this ana-
lysis (patient selection bias) as well as accurate measurement
of brain tumor progression using brain MRI (true vs.
pseudoprogression).
In the third study, Hager et al. [33] applied AM-RF-HT
(70–150W, 60min) in 80 patients with liver metastases of far
advanced stages of colorectal cancer and retrospectively ana-
lyzed the results. For all patients, they started with one
course of 8 AM-RF-HT biweekly (without chemotherapy) in
the liver and found an overall biochemical response (CEA
and CA-19-9 decreased below 75% of initial values) in 25%
of the patients. A total of 50/80 patients received only AM-
RF-HT, whereas 30/80 patients later received chemotherapy
(mytomycin þ 5-fluorouracilþ folinic acid) during the follow-
up period. The authors reported remarkable survival times
and objective tumor regression (CT-scans, ultrasound) in
these patients. Again, AM-RF-HT alone appeared to cause sig-
nificant tumor regression.
No firm conclusions can be drawn due to the retrospect-
ive design of the above studies. However, the clinical data
suggest that AM-RF-HT at moderate temperatures <40 C
should have non-thermal effects on various tumors.
3.2. Clinical applications of RF-EMF in the intermediate-
frequency range 100–300 kHz
RF-EMF in the intermediate-frequency range 100–300 kHz,
also known as tumor-treating fields (TTF), was first studied in
patients with recurrent GBM and then clinically validated as
an additional modality in first-line GBM treatment [25,32].
Treatment was delivered through four transducer arrays with
nine insulated electrodes placed on the shaved scalp accord-
ing to the planning software [34]. TTF was started 4–7weeks
after the end of simultaneous radiochemotherapy (e.g.,
together with the TMZ maintenance therapy) and was run
every day for at least 18 h for a maximum duration of
24months. The median survival was significantly improved
from 16months (TMZ alone) to 21.9months in the TTF
experimental group (p< 0.001). SAR or E-field distributions in
the brain were calculated using the finite-element method
[35,36]. Ballo et al. [37] used the Sim4Life quasi-electrostatic
solver to ascertain E-field or SAR distributions and verified an
association of overall survival and TTF E-field strength,
achieving a better outcome for mean E-field strength
>100 V/m. The SAR varied in the range of 0.3 to 3.2W/kg
that is not sufficient for any anti-proliferative thermal effect.
Even though preclinical findings, dose-response relationships,
and clinical outcomes of the study were consistent, the
results were called into question. We note that the patients
from the experimental treatment group are likely to have
received superior medical care, as they were treated mostly
within tertiary referral centers, which might also improve
overall survival [38]. Furthermore, the long-term and nearly
permanent wearing of the “electric hood” is associated with
severe restrictions for the affected patients, which limits the
quality of life of patients. In addition to newly diagnosed
and recurrent glioblastoma, various other oncological appli-
cations of TTF are being studied, such as brain metastases,
lung cancer, malignant mesothelioma, pancreatic cancer,
HCC and ovarian cancer (www.novocuretrial.com). Mun et al.
[39] referred to TTF as the fourth modality in cancer therapy
and further described the potential for clinical applications
on the head, thorax and abdomen. An indisputable advan-
tage of TTF is its applicability to large anatomical regions
throughout the human body, while a disadvantage is a need
for permanent and long-term exposure to TTF.
3.3. Clinical application of AM-RF at 27.12MHz
Clinical experience with AM-RF at 27.12MHz, also referred to
as the TheraBionic device, is limited to a few case series
where the treatment was applied alone in advanced cancer.
Barbault et al. [26] described the identification of tumor-spe-
cific AM frequencies using a simple RF generator at
27.12MHz that powers an intrabuccal spoon-shaped applica-
tor. The maximum SAR deposited in the body was estimated
to be below 2W/kg. Therefore, temperature increases in any
tissue or tumor are negligible. AM is possible between
0.01 Hz and 150 kHz with a modulation depth of 85%.
Variations in the radial pulse amplitude are claimed to indi-
cate a tumor-specific AM frequency, which seems surprising.
However, Sharma et al. [40] recently explained that the Ca2þ
channel CACNA1H might be expressed in tumors and small
vessels (endothelial and smooth muscle cells) that could
affect the pulse amplitude.
In a total of 163 patients with various cancers, Barbault
et al. discovered 1524 modulation frequencies between 0.1
and 114 kHz using their bio-feedback technique [26]. HCC,
pancreatic cancer, ovarian cancer, BC and prostate cancer
commonly exhibited frequencies between 1.8 and 10.5 kHz.
Typically, more tumor-specific frequencies were found in
advanced and progressive tumors. A total of 28 patients with
advanced cancer received a low-level AM-RF at 27.12MHz,
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which implies a self-administered treatment of 60min, three
times a day for a mean treatment duration of months (range,
1–50.5months). For 7/28 patients (25%), complete remission
(1/28), partial remission (1/28) or stable disease (5/28) were
documented according to the RECIST criteria. These findings
suggest non-thermal therapeutic effects of AM-RF with
tumor-specific AM frequencies.
Costa et al. [27] conducted a phase I/II study in 41
patients with advanced HCC, who had either failed standard
therapy or had severely impaired liver function limiting any
kind of systemic treatment, and used AM-RF at 27.12MHz as
monotherapy. Of these patients, 4/41 had partial remission
and 16/41 stable disease for 12weeks (49% long-term con-
trol), with 4/41 patients becoming long-term survivors (>3
years). These data confirmed the potential of using AM-RF
at 27.12MHz.
4. Preclinical studies
Numerous preclinical studies have investigated the non-ther-
mal effects of EMF. Investigations mainly dealt with the pos-
sible risks of EMF at low levels without a relevant
temperature increase. Epidemiological studies [41,42] have
focused on EMF either in the extremely low-frequency range
(ELF; <3 kHz) or in the RF-range (3 kHz up to 300GHz). EMF
exposure at ELF is ubiquitous and is mainly caused by elec-
tric lines and associated grounding systems, while wireless
communication applications are the source of RF exposures.
Organizations such as the World Health Organization and the
International Commission of Non-Ionizing Radiation
Protection stated that although epidemiological studies have
suggested links between EMF exposure and health effects,
they could not provide a reliable interpretation [43–46].
Forschungsgemeinschaft Funk thoroughly examined the
possible non-thermal effects of weak EMF (http://www.fgf.de/
index2.html) from 1992 to 2009 in Germany and published
the results in 2009. The REFLEX (Risk Evaluation of Potential
Environmental Hazard from Low Energy Electromagnetic
Field Exposure Using Sensitive in vitro Methods) study was
an elaborate European union (EU) project from 2000 to 2003
involving 12 research groups from seven countries.
Standardized exposure systems for EMF magnetic fields [47]
and RF exposures at 900MHz [48] and 1800MHz [49] were
constructed according to development guidelines [50].
Nevertheless, the results were highly controversial and not
reproducible, indicating the difficulties in obtaining clear
conclusions in this field of research.
In the actual extensive “Handbook of Biological Effects of
Electromagnetic Fields” (two volumes with 1150 pages) the
technical term “non-thermal” is not even mentioned [51,52]
but the issue was discussed as controversial [53,54].
In the previous Section 3, we listed recent clinical studies
(mEHT, TTF and TheraBionic) that strongly suggest the exist-
ence of non-thermal effects. As a result, we focused on the
associated preclinical investigations, which have provided
the prerequisites for these clinical applications. It is precisely
this recent clinical and preclinical work that is most likely to
contribute to the controversial discussion.
The biological endpoints of cells or animal tumors are an
important issue. Clearly, the clonogenic assay is the gold
standard if radiotherapy dosages or thermal doses are directly
transferred to the clinics. However, the question here is
whether there are non-thermal effects and which mechanisms
are underlying. Then other biological endpoints than clonoge-
nicity are also of interest, e.g., apoptosis, damage-associated
molecular pattern (DAMP) and others. In spite of the huge
number of literatures on this issue, we are not at the point to
formulate a dose concept for non-thermal effects.
4.1. Amplitude-modulated (AM)-RF-HT at 13.56MHz
Figure 1 depicts the experimental setup for evaluating the
biological effects of AM-RF-HT on cell suspensions as the pre-
clinical counterpart of mEHT or oncothermia; the findings
can easily be compared to the effects of WB-HT [55,56]. In
parallel to the clinical application, the RF source generates a
carrier frequency of 13.56MHz with an adjustable AM start-
ing at a given minimum modulation frequency f and then
declining with 1/f (pink noise) with a selected modulation
index m (LabEHY-200, Oncotherm Kft., Budapest, Hungary) as
described in detail in [57]. Temperatures are typically meas-
ured in the center of probes of <1ml (dimensions <1 cm)
and in the surrounding distilled water by fluoro-optic sen-
sors. Then the probe temperature represents the maximum
temperature and is controlled by the RF power. Temperature
deviations in the probe of a few tenths of a degree are pos-
sible but are further reduced if the surrounding water is
warming up near to the probe temperature. However, the
crucial parameters SAR or E-field in the specimen are not
always clearly defined in preclinical studies with this applica-
tor (see Figure 1 legend). SAR can be determined by measur-
ing the rate of temperature increase over time (C/min).
The bioheat-transfer equation predicts SAR of
200 300W/kg to heat a sphere of 1 cm diameter from 37 C
to 42 C. The SAR declines below 100W/kg when the ambi-
ent temperature rises above 40 C [58]. That is the typical
Figure 1. Design of an experimental setup to expose a cell suspension (green)
to AM-RF-HT [55]. A mean E-field emerges between the electrodes of the cap-
acitor C generated by the voltage VC. The capacitor C in series with an inductiv-
ity L (with loss resistance R) establishes a resonance circuit with resonance
frequency RF [56]. It is desirable that temperature T (set and maintained using
a flow system) and SAR (set by VC) can be selected separately. If the resonance
condition f¼ 2p(LC)1/2 is met, the system is well matched, i.e., in resonance.
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description of an experiment according to Figure 1—not far
away from the clinical situation [55]. The formation of select-
ive small-volume overheating in regions of approximately
1mm extension would require excessive SAR > 10,000W/kg
or even SAR >1,000,000W/kg for areas of 0.1mm extension
etc. —as outlined in a series of publications about point
heating or nanoheating [58–62]. We note that a simple
arrangement of a 1ml cell suspension in a capacitor cannot
generate such high SARs that would be required to generate
hot spots on a microscopic level.
Another arrangement is applied for in-vivo experiments
with mice tumors. Here, an electrode of 1.8 cm diameter is
positioned on tumors of a few millimeter size with a neutral
electrode on the opposite. As illustrated by [63] SAR
between 100 400W/kg are generally required to heat such
small tumors to 40 42 C in accordance with our own
experience (unpublished results).
Obviously, in case of mEHT, the preclinical studies use 10
times higher SARs than clinically attainable resulting in only
3 times higher E-field strengths. Higher electric field
strengths can facilitate the detection of non-thermal effects
and lead nevertheless to valid results if relevant thermal
effects can be excluded.
The data show higher rates of apoptosis for AM-RF-HT
(typically 42 C for 30–60min) in comparison to standard
WBHT at the same temperature [64]. The greater effective-
ness of AM-RF-HT compared to infrared (IR) HT for nude
mice xenografts in vivo [65] or WBHT for cell suspensions
(human cancer cell lines) in vitro [66–68] has been demon-
strated by microscopic detection of dead cells or apoptotic
cell death. A 30min treatment with AM-RF-HT at 42 C was
3.2-fold more effective than IR-HT at 42 C. Notably, 30min
of AM-RF-HT at 38 C was still 2.6-fold more effective. In cell
suspensions, the apoptosis-inducing effect of AM-RF-HT at
42 C was similar to that of WBHT at 46 C. Apoptosis was
associated with increased caspase activation, calreticulin
expression, and intra-/extracellular HSP70 expression. Andocs
et al. [69] found a complex dependency of AM-RF-HT efficacy
on temperature, i.e., increased efficacy from 39 C to 42 C
(45% dead cells) and then a (slight) decrease at 43–44 C
(30% dead cells) suggesting that for temperatures <43 C,
AM-RF-HT generates considerably more dead cells than
WBHT, although the temperature dependency for AM-RF-HT
and WBHT might be different.
Several preclinical studies employed 1–3 sessions of AM-
RF-HT (42 C, 30–60min) and measured the apoptosis rate in
xenografts and/or tumor cell suspensions [66,70–76].
Researchers consistently found high rates of apoptosis—
which were markedly higher than those expected for trad-
itional heat treatment at 42 C—in comparison to the control
groups. Further, several indicators of cellular stress, such as
elevated HSP70, calreticulin, HMGB1 and damage-associated
molecular pattern (DAMP) signals are associated with AM-RF-
HT alone [63,72,75,77]. AM-RF-HT induced significantly higher
HSP-levels than WBHT at the same temperature [67]. It is
known that DAMP signals can support immunogenic cell
death (ICD) in response to chemotherapy, radiotherapy,
immunotherapy or immune checkpoint inhibition therapy
[78,79]. In fact, for symmetrical tumors (both femoral legs in
mice), treatment-related effects were also observed in
untreated tumors (compared to the sham controls) [75,80]. In
a CT26 murine colorectal cancer model, Tsang et al. [66]
found a synergism between intratumoral dendritic cell injec-
tion and AM-RF-HT, and a systemic effect (prevention of
contralateral tumor seeding). Thus, AM-RF-HT can support
local and systemic ICD-mediated tumor killing. The abscopal
effects of AM-RF-HT were clinically confirmed [23].
Combination treatment of AM-RF-HT and RT [81–84] was
found to result in greater tumor damage, particularly if AM-
RF-HT was immediately—or at least within 4 h—followed by
RT in fibrosarcoma allografts (in C3H mice) and various can-
cer cell lines (9 L, MCF-7, Panc-1). Interestingly, the opposite
order (RT followed by AM-RF-HT), which is common for cRF-
HT, was less effective.
AM-RF-HT has been used in combination with chemother-
apeutic agents. The cytotoxic effect of doxorubicin was
potentiated when doxorubicin was preceded by two 30min
treatments of AM-RF-HT at 42 C [76]. In another study, can-
cer cells (HepG2, A 549, U87MG and CT26) were treated with
liposome-encapsulated doxorubicin (LipidoxVR , Stockholm,
Sweden) and then subjected to WBHT (42 C, 30min) or AM-
RF-HT (42 C, 30min) [85]. LipidoxVR plus AM-RF-HT exhibited
higher cytotoxic effect (viability 10–20%) than LipidoxVR plus
WBHT (50–75%) and LipidoxVR at 37 C (80–95%).
Interestingly, most available references do not specify the
parameters of the AM (f and m) adjusted for the AM-RF-HT.
We determined a typical default setup in the clinical device
EHY 2030, amounting to f 60Hz and m¼ 0.2, and compar-
able parameters are assumed for the preclinical devices (own
unpublished measurements). Wust et al. [55] detected
already for RF-HT (without additional AM) more antiprolifera-
tive effects than those in WBHT (80–100% vs. 45–50% clono-
genicity in HT-29 and SW480 cells). This is in line with our
experiences with cRF-HT. The importance of any type of AM
is currently under investigation. It should be noted that dif-
ferent biophysical mechanisms may underlie RF- or AM-RF-
induced non-thermal effects (see below).
4.2. RF-EMF in the intermediate-frequency
range 100–300 kHz
Pairs of insulated wires or electrodes are suitable for generat-
ing low-intensity RF-EMF of 100–300 kHz in cell cultures or
tissues. In vitro studies on eleven different types of cancer
cell lines and in vivo studies on mice tumors showed arrested
proliferation, cell destruction, and reduction in tumor growth
[86]. A 24 h exposure of EMF with moderate strengths of
100–140 V/m (comparably low SAR of approximately 5–10W/
kg without considerable temperature elevation) resulted in a
significant decrease in growth rate (relative to that of the
control) of 10–90% depending on the cell line. This applica-
tion was labeled as tumor treating fields (TTF).
Antiproliferative effects increased with E-field strength and
depended on frequency and cell line (e.g., maximum for
B16F1 cells at 120 kHz and F-98 cells at 170 kHz). Kirson et al.
[86] identified two E-field effects, which are not temperature-
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dependent. First, the E-field polarizes and orients tubulin
dimers and other charged macromolecules in the direction
of the E-field during the early phases of mitosis, which inter-
feres with proper chromosome alignment and separation.
Second, during cleavage, the E-field is strongly inhomogen-
eous, exerting an electric force on all intracellular charged
and polar macromolecules. Since dividing cells are disturbed
and sometimes destroyed, the authors suggested a novel
treatment modality for cancer. Another paper extended the
investigations to additional cell lines and animal tumor mod-
els [87]. The combination of chemotherapy (paclitaxel, doxo-
rubicin, and cyclophosphamide) with TTF resulted in strong
sensitization [88]. Silginer et al. [89] supplemented preclinical
information for several glioma cell lines and identified
100 kHz as the most effective frequency for glioma. TTF also
hampered the invasiveness and migration of glioma cells.
Importantly, glioma cells responded to TTF independent of
MGMT status and/or TMZ resistance.
4.3. AM-RF at 27.12MHz
Barbault et al. [26] exposed cancer patients to low-level AM-RF
(<2W/kg) with a carrier frequency of 27.12MHz and selected
modulation frequencies from 0.01Hz to 150kHz with a high
modulation index of 0.85, which does not cause any tempera-
ture increase. This system is also referred to as TheraBionicTM
(Ettlingen, Germany). The authors briefly described a bio-feed-
back method (measuring skin electrical resistance, pulse ampli-
tude, and blood pressure) and identified a variety of cancer-
specific modulation frequencies (see also [90]). This low-level
AM-RF was evaluated in three preclinical studies.
Zimmerman et al. [91] utilized cancer-specific modulation
frequencies identified in hepatocellular carcinoma (HCC) and
breast cancer (BC) cell lines. They described the antiprolifera-
tive effects associated with changes in gene expression in two
representative HCC cell lines (HepG2 and Huh7) exposed to
AM-RF for 21h in sevendays (3h per day) or longer with
HCC-specific AM frequencies. A commonly used tritium incorp-
oration assay determined the growth inhibition that persisted
over a period of sevenweeks. We highlight some interesting
results of this early preclinical study. First, significantly lower
growth inhibition was measured using randomly chosen (non-
specific) or BC-specific AM against HCC cells, instead of HCC-
specific AM. Second, HCC-specific AM did not affect the prolif-
eration of BC cells (here MCF-7) or normal hepatocytes (THLE-
2). Third, within the entire SAR range (from very low levels of
0.05 to 1.0W/kg), they measured significant antiproliferative
effects. Fourth, growth inhibition depended on the exposure
time. They did not observe any effect for reduced exposure
times such as 1 h per day for seven days or 3 h per day for
three days but achieved the same level of effect for longer
exposure times such as 6 h per day for seven days.
Application of HCC-specific modulation frequencies for more
than 21h resulted in mitotic spindle disruption in more than
60% of HCC cells. Therefore, for both approaches (TTF and
TheraBionic), a minimum exposure time was required to
achieve a significant antiproliferative effect but this effect did
not always increase with prolonged exposure time.
These results were confirmed and explored in two recent
studies. Jimenez et al. [92] exposed additional HCC cell lines
(HepG2, Hep3B, Huh7, HCCLM3 and MHCC97-L) to the same
AM-RF (27.12MHz with low SAR between 0.03 and 0.4W/kg)
for 3 h daily for seven days. They found antiproliferative
effects only for AM-RF with HCC-specific AM. Interestingly,
growth inhibition was associated with increased intracellular
Ca2þ resulting from Ca2þ influx through a special T-type low
voltage-gated Ca2þ-channel (VGCC) CACNA1H [93–95], which
appeared to be selectively sensitive to HCC-specific modula-
tion frequencies. In vivo experiments with mice carrying
human HCC xenografts confirmed the inhibition of tumor
growth by AM-RF exposure with HCC-specific AM.
Sharma et al. [40] described the same pattern for human
BC cell lines (T47D, BT-474, SKBR3, MDA231 and MDA-MB-
453) with different BC-specific AM. Additionally, after intra-
cranial injection of HER2-positive or triple-negative BC cells
into SCID mice, the implanted brain metastases were
exposed to AM-RF with the same low SAR (0.03–0.4W/kg)
3 h each day until the experimental endpoint. For both cell
types, they found significant suppression of metastases and
tumor growth, resulting in significantly improved brain
metastasis-free survival. Again, AM-RF-EMF with BC-specific
frequencies in BC cells was associated with increased Ca2þ
influx through the same CACNA1H channel. However, an
exact biophysical mechanism has not yet been described.
5. Model approaches to describe non-thermal
antiproliferative effects
Biophysical mechanisms were not presented to the best of
our knowledge until now to explain the controversial non-
thermal effects, in particular, in the clinically relevant RF
range from 1 to 150MHz. This lack of theory building is a
common argument against the existence of non-thermal
effects. In fact, works that refute the existence of non-ther-
mal effects are predominantly of a theoretical nature
[43,44,46,96–100]. How else can you deal with something
that does not exist?
Predominantly in past experiments, higher frequencies
(microwaves up to terahertz) were investigated with regard
to their non-thermal resonance effects [101,102]. Therefore,
theoretical considerations mentioned above have attempted
to refute such resonances in macromolecules, e.g., DNA or
enzymes [44,97–99,103]. These high frequencies (>300MHz)
are, however, of minor importance for clinical hyperthermia
because of their limited penetration depth.
In the following section, we focus on the membrane
effects of EMF in the lower RF range (<100MHz).
5.1. Nanoheating
The term nanoheating (formerly known as point heating)
refers to the deposition of a very high SAR in a microscopic
volume, e.g., a protein cluster (nm to mm size) in the cell
membrane or the cytoplasm. This theoretically fascinating
therapeutic approach occupied many researchers in a series
of publications, beginning at the time of World War II
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[58–62]. The underlying problem can be solved by an analyt-
ical solution of the partial differential equation for the tem-
perature distribution, which ultimately represents a diffusion
equation with a transport term (perfusion) known as the bio-
heat transfer equation. In the cited works it was consistently
shown that a circumscribed SAR increase in regions <1mm
must be unrealistically high in order to generate a thermal
effect (e.g., SAR > 10,000W/kg for a 1mm sphere). On the
other hand, with realistic SAR increases, only minimal tem-
perature increases of fractions of 1 C are expected. In con-
clusion, non-thermal antiproliferative effects, at least in part,
must exist to explain preclinical and clinical data.
Nanoheating is specially investigated after the administra-
tion of nanoparticles in the target and exposure to an alter-
nating magnetic H-field [104–106]. Analysis of available
ferrofluids and tolerated H-fields (frequency and amplitude)
shows that effective heating of lesions <1 cm is difficult.
Thus, nanoheating, without nanoparticles, appears even
more difficult.
Based on current technology, typical incident E-field
intensities under clinical conditions are in the range of
E¼ 50–350 V/m corresponding to SAR ¼ 1–60W/kg.
Uncomplicated and cost-effective devices achieve a low SAR
of 5–15W/kg (E¼ 100–170 V/m). These E-fields are negligible
compared with the E-fields between the inner and outer sur-
faces of the lipid bilayer of E> 106 V/m associated with the
resting potential of approximately 30–100mV at membranes
of 4–5 nm thickness. However, the distribution of electrical
constants such as the relative permittivity er and conductivity
r (in S/m) is inhomogeneous in living tissues and might gen-
erate higher E-fields caused by electrical boundaries com-
pared with the incident E-field [107]. The field distribution is
determined by solving Maxwell’s equations, which is certainly
a challenge at the microscopic level. In particular, Maxwell’s
4th equation causes elevations of E at the elec-
trical boundaries.
Eibert et al. [108] investigated this issue and performed
an electromagnetic and thermal analysis of an exposed struc-
ture depicted in Figure 2. They showed that with such
arrangements, voltages of a few millivolts arise on and in the
membrane, which is in the percentage range of the resting
membrane potential. In Figure 2, the electrical constants er
and r are taken for the frequency range of 70MHz.
Figure 3 schematically shows the frequency-dependent
behavior of er in living tissues [109,110], indicating the range
of cRF-HT with er 80 (above 70MHz). The so-called d-disper-
sion formed by proteins, protein-bound water and organelles
[110] leads to this well-known plateau representative of APA
technology (70–120MHz). However, the d-dispersion also
causes a 10-fold higher er of 1000 at 10–30MHz (of AM-RF),
while the a- and b-dispersions result in a 1000-fold higher er
> 100,000 at intermediate frequencies (100–300 kHz). Such a
high er might create a large E of 500 V/m (corresponding to
local SAR of 120W/kg) in certain microscopic areas (as shown
in Figure 2) if the AM-RF-HT-technique at 13.56MHz is
applied (or other CS around 10MHz). This fact might partially
compensate for the technological advantage of the APA
technique at RF around 100MHz.
In the intermediate-frequency range, local E-field peaks
along the membranes can be large (100,000 V/m) in add-
ition to the described specific mechanisms during cell div-
ision. This might be a further explanation for the
effectiveness of RF-EMF in the intermediate-frequency range.
Papp et al. [111] investigated the power absorption in
transmembrane protein clusters (rafts) with an assumed
diameter of 1mm and enhanced permittivity and conductivity
in comparison to the adjacent membrane layer. They created
a 3D model of the raft embedded into the membrane and
simulated the E-field distribution using CST EM Studio
(Computer Simulation Technology software, Darmstadt,
Germany). Assuming realistic excitations of 100 V/m E-field
elevations up to 300 V/m (SAR of 40W/kg) occurred at the
Figure 2. Three-dimensional configuration analyzed by Eibert et al. [108] using sophisticated numerical methods. They found for this special arrangement that the
high electrical jump between the extracellular fluid (er ¼ 70, r¼ 1.2 S/m, blue) and fatty or connective deposits (er ¼ 3, r¼ 0.002 S/m, yellow) cause high E-fields
of some 1000 V/m (and SAR of 500W/kg) at a lipid bilayer (membrane) between. Voltages as high as millivolts can be generated in these membrane sections. This
analysis is valid for RF> 70MHz (see dispersion curve in Figure 3).
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rafts and are probably of minor effect. We note that the
authors [111] assumed a much higher excitation of 50,000 V/
m and resulting SAR peaks that are clinically unrealistic.
In summary, current theoretical approaches do not indicate
that energy transfer by EMF to biological macromolecules can
disturb their function or even cause chemical conversions.
5.2. Biophysical processes on transmembrane
ion channels
Preclinical and clinical experience with AM-RF-HT at
13.56MHz and AM-RF at 27.12MHz suggest that non-thermal
mechanisms exist, which stress and finally damage the
exposed cells. Suitable AM might enable or at least enhance
these processes. The non-thermal effects of AM-RF could
arise from electrical disturbances at the membranes.
Therefore, we examined the ion channels more closely.
We validated the non-thermal effects of RF at 13.56MHz
without AM in a typical preclinical experiment using LabEHY-
200 [55]. For a better understanding, we developed a model
for ion channels based on textbook knowledge [112–115].
Figure 4 shows an example of a Ca2þ channel, which was
proven to be particularly important for non-thermal effects.
This model is also extrapolatable to potassium (Kþ), sodium
(Naþ), chloride (Cl–) or hydrogen (Hþ) ions. The basic ele-
ments of a typical ion channel are the entrance (here outer)
pore, which has a mechanism for opening and closing (gat-
ing) with some selectivity for the particular ion (here Ca2þ), a
cavity to collect the ions, and the selectivity filter as the
most important and highly specific part for the particular
ion. The ion gains the dehydration energy by a specific
chemical reaction with carbonyl oxygen atoms lining the
selectivity filter, stalls in the filter, and can only exit by
exploiting electrostatic repulsive forces if the next ion enters
from the cavity [112].
We assume that every channel act like a diode because
ions can only be directed along the electrochemical gradient.
Our example (Figure 4) shows a huge Ca2þ gradient between
the extracellular concentration of 1.3mmol/l and intracellular
concentration of only 100 nmol/L (>10,000-fold). Then, the
equilibrium (Nernst) potential for Ca2þ is UCa  250mV,
which is far from the typical membrane potential of –60mV.
This electrochemical gradient is enormous, causing a strong
tendency for calcium influx and intracellular calcium overload
if the calcium channel is open. Instead, in the case of potas-
sium, the Kþ equilibrium (Nernst) potential of UK ¼ –95mV is
below the membrane potential of 60mV. Therefore, Kþ ions
flow from intracellular to extracellular to bring the mem-
brane potential nearer to the Kþ equilibrium potential. Thus,
Figure 3. Frequency dependency (dispersion) of permittivity er. The plateau
with er  80 characterizes the conventional RF-HT for APA technology (50MHz
to GHz). The d-dispersion causes much higher er of  1000 at 10MHz in favor
of the capacitive technology. In the TTF range of some 100 kHz er > 10,000 at
arrangements of macromolecules, which might induce huge E-fields under spe-
cial conditions (see Figure 2).
Figure 4. Model of a calcium channel to estimate RCa and GCa that we used as a template for ion channels [112]. The ion channels act like diodes with forward dir-
ection along the electrochemical gradient (for calcium from extra- to intracellular). The selectivity filter is magnified for clarification. There is a large electrochemical
gradient toward intracellular due to the difference between the membrane potential of -60mV and the Ca2þ equilibrium potential of 250mV. High concentration
gradients >10,000 predispose cells to excessive calcium influx. Thus, disequilibrium of intra-/extracellular calcium concentrations is more probable for calcium than
for other electrolytes.
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a potassium channel acts like a diode with the forward direc-
tion from intra- to extracellular.
The resistances of ion channels can be estimated using
basic electrical principles (e.g., RCa ¼ 323GX or RK ¼ 4.3GX,
see [55]) and the surrounding membrane contributes a capaci-
tance C. Figure 5 (right) shows the equivalent circuit diagram,
which is basically a diode in series with a low-pass filter RC
(with resistance R and capacitance C). Thus, the voltage associ-
ated with the RF E-field along the channel (i.e., perpendicular
to the membrane), is rectified and smoothed. In the case of a
pure sinusoidal RF wave (E¼ 200 V/m assumed), a direct volt-
age of 1mV is emerging (see dotted line). Additional AM
with a single modulation frequency, after demodulation, yields
the solid sinus curve overlaying this direct voltage. Direct volt-
age and superimposed alternating voltage might exert differ-
ent effects on the channel (see below). In certain regions with
electrical inhomogeneities, E-fields can be higher (see the pre-
vious section) and the generated direct voltage can approach
the millivolts range under special conditions (Figure 2) [108].
While the ion flux through a single channel caused by
some microvolts to millivolts might be considered ineffective,
a mean channel density of 1 channel/mm2 (i.e., 2000 channels
in the membrane that point in the direction of the E-field)
and an exposure time of 30–60min (1800–3600 s), can
enhance the stress on the cell by a factor >106. This con-
trasts with the fact that the channels are often (but not
always) closed.
Even such a small voltage offset of 1 mV along >1000 ion
channels for >1000 s will cause a relevant disequilibrium of
ions in the affected cells, which can be much higher than
the complete ion content for sodium, chloride, and protons
and >100-fold larger than the intracellular calcium content.
Table 1 (1st column) shows the relative intracellular ion
increase resulting from Ohm’s law. However, it is supposed
that mostly, fast chemical reactions control the flux through
the ion channel (facilitated diffusion), which considerably
accelerates the exchange (2nd column). A DC voltage of 1 mV
(or the associated E-field of 200 V/m) causes a drift velocity
vX of the ion X. Then, we estimate the maximum flux
through the selectivity filter dividing vX by the hydration
diameter dX, if we assume that the ions pass the channel
(and, in particular, the filter) in a single file with maximum
rapidity. Wust et al. [55] provided further details of the mod-
els, basic equations, and calculations.
Table 1 summarizes the results and suggests that
increased intracellular Ca2þ most likely explains non-thermal
damage to cells. Indeed, researchers reported increased intra-
cellular calcium in association with non-thermal antiprolifera-
tive effects of AM-RF-HT [68], AM-RF at 27.12MHz [40,92],
and RF-EMF in the intermediate-frequency range [116].
Researchers identified VGCC of the T-type CACNA1H (in HCC
or BC) or L-type CACNA1C (glioblastoma) as sensitive to EMF
used with AM-RF at 27.12MHz or RF-EMF in the intermedi-
ate-frequency range and causal for intracellular Ca2þ
Figure 5. Left: Typical tumor environment characterized by isolated tumor cells surrounded by extracellular water. Middle: Simplified model of ion channels in the
membrane (e.g., potassium) showing the internal pore, cavity and selectivity filter. This model is an archetype for other ion channels. Right: Equivalent circuit dia-
gram of an ion channel according to the ion channel model of Figure 4. After rectification of the amplitude-modulated (AM) carrier radiofrequency (RF) (10MHz)
a low-pass filter (specified by RC) generates a mean DC voltage (1mV for SAR of 25W/kg) with a superposed sinus oscillating with the modulation frequency in the
kHz range (red solid line). For RF of 10MHz the condition RC  107 s holds.
Table 1. Estimated fluxes through ion channels caused by 1 mV either derived applying Ohm’s law or assuming maximal facilitated diffusion (passage in file)
and their impact on ion imbalances assuming 1000 channels and 1000 s exposure time resulting in an enhancement factor 106. The highest imbalance is


















Kþ 1500 out 38,000 out 5	 1010 0.03–0.76 15.2 0.25
Naþ 300 in 20,800 in 2	 109 0.45–10.4 10.4 0.35
Cl- 1100 in 39,500 in 2	 109 0.54–19.4 15.8 0.20
Hþ 10-2 in 120,800 in 3	 104 0.4–5	 107 72.5 0.60
Ca21 19 in 30,800 in 3	 104 >100–1600-fold 12.3 0.30
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overload. Pall et al. [117] listed 23 additional studies that
demonstrated activation of VGCC by EMF of different kinds.
Notably, one single open Ca2þ channel indicates that the RF
enforces a calcium overload of the cell many times over the
regular content with the preconditions of Table 1 (bottom
line). Interestingly, T-type VGCCs require only a moderate
depolarization of 10–20mV for activation/opening [118] and
are probably particularly sensitive to influences on the
cell membrane.
An overload of intracellular calcium and protons and/
or a decline in the intracellular pH will certainly harm the
cell. Additionally, intracellular overload of NaCl may cause
cell edema/swelling, leading to cell death, and intracellu-
lar loss of Kþ may promote apoptosis [119]. Ion channels
provide the key to understanding the non-thermal effects,
even though the exact biochemical mechanisms
are unknown.
Abnormalities of ion channels in tumor cell lines have
been described in numerous publications [119–126].
Ashrafuzzaman’s textbook (Chapter 8) provides a summary
[127]. In tumor cells, with increasing aggressiveness, certain
channel families are often overexpressed, e.g., transient
receptor potential (TRP) channels. They are responsible for
calcium transport, proton transport (pH regulation), and
water exchange (aquaporins). T-type calcium channels are
broadly expressed in various malignancies [93]. Differences
in ion channels (channelomes) in tumors and normal tis-
sues can contribute to an increase in the therapeutic quo-
tient. Both the duration and sequence play a decisive role
in the non-thermal effects and may differ significantly from
cRF-HT.
5.3. Frequency-dependent effects on cells
Frequency-dependent effects caused by particular modula-
tion frequencies on an RF carrier were described by two
research groups more than 40 years ago [128,129]. Both
described a calcium release in brain tissue caused by AM-RF
of 147MHz with an ELF of 10–20Hz at low intensities of
1W/kg; in a control without AM, they found no effect.
Later, researchers described comparable effects in brain tis-
sue exposed to ELF directly without a carrier [130] and noted
its dependence on temperature [131]. These results are con-
troversial [96,100,132–134]. We note that in some refuting
studies pulsed microwaves were used, which is clearly not
the same as AM-RF (see below).
An analysis of the experimental data reveals a non-ther-
mal gain in effectiveness through AM of the RF with modula-
tion frequencies hertz to 20 kHz (audio frequencies).
Preclinical and clinical experience with the AM-RF-HT indi-
cates effectiveness for lower AM frequencies in the range of
100Hz to a few kilohertz considering the pink-noise
approach, which typically starts at a minimum frequency of
100Hz. Instead, experiences and data using AM-RF at
27.12MHz predominantly indicate frequencies >1 kHz (up to
20 kHz). Increased efficacy with duration and number of
applications is always observed.
For a reasonable explanation of the resonance frequencies
generated by AM-RF-HT on cells (Hz–20 kHz), we refer to our
model of an ion channel. Because the dehydrated ions are
trapped in the selectivity filter, every periodic force is trans-
mitted to the adjacent membrane. As depicted in Figure 6,
the membranes consist of vibratory sheets or tiles, which are
isotropic or at least six-fold symmetric. Such membrane
Figure 6. Schematics of a single section of the cell membrane that is excited by the ion channel to vibrate. This membrane section perpendicular to the incident
wave behaves like a sheet a	 b with supported edges. Such a vibratory structure can be excited to natural bending oscillations in the frequency range from hertz to
kilohertz depending on the dimensions a, b and the stiffness of the membrane described by the Young’s modulus Y (see text). Excitable tiles with larger extensions
can be composed of these sections with an increased number of exciting ion channels. The Eigen frequency declines with increasing dimensions a and b, given in mm.
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portions are characterized by only two elastic parameters
[135,136]. The first parameter is the volume compression
modulus KV, which amounts to 10
7–108 Pa. These consistently
high values of the compression modules for lipid bilayers
and cell membranes reflect the incompressibility characteriz-
ing both solids and liquids [135]. The second parameter
describes the fluidity (elasticity) of membranes and may vary
considerably (see below). Poissons ratio r is a suitable par-
ameter to describe fluidity. For r¼ 1/3, the stiffness is high
and describes a solid. Instead for r ) 1=2, the membrane
increasingly takes on the properties of a liquid. The corre-
sponding elasticity parameters are either Young’s modulus Y
(also called stiffness) or shear modulus m (also called torsion).
The basic relationships between elasticity parameters are
derived according to [136 §5]:
Y ½Pa
 ¼ 3 	 ð1 – 2rÞ 	 KV
l ½Pa
 ¼ Y=ð2 	 ð1þ rÞÞ
Both decline (and finally approach zero) in comparison to
KV as r goes toward 1=2.
Assuming the Young’s modulus Y of a membrane section
in Figure 6, the resonant frequencies for the bending vibra-
tion of this sheet with supported edges can be calculated
accordingly [136, § 25]:
f ½kHz
 ¼ 120 	 Y1=2 ðn=a2 þm=b2Þ ; n, m ¼ 1, 2, . . .
(1)
with Y in Pa, a and b in mm.
For n¼m¼ 1, we obtain the fundamental oscillation and
for n, m> 1 high-frequency harmonics.
For Y¼ 500 Pa and a¼ b¼ 10 mm, we calculated a funda-
mental resonant frequency f¼ 53Hz assuming a vibration of
the whole membrane face. If only parts of the membrane
are excited, for example, a¼ b¼ 1 mm, we calculate
f¼ 2.7 kHz. Depending on the stiffness Y [Pa] of the mem-
brane and the extension a, b [mm] of the oscillating sheet,
we predict the resonant frequencies in the hertz and kilo-
hertz ranges that match the modulation frequencies used in
the previous sections.
The mechanical properties of tumor cells and normal cells
may strongly differ [137,138]. Generally, tumor cells are more
deformable and elastic in correlation with higher adhesion,
migration, invasiveness, and metastasis formation. Table 2
shows the upper lines for a typical KV ’ 107 Pa that theoretic-
ally, the calculated Y of a cell membrane (using Equation 1)
decreases from very high Y¼ 107 Pa (for r¼ 1/3 indicating a
behavior like a solid) down to Y¼ 600Pa, if r¼ 0.49999
describes a fluid-like behavior. The measured Y in Table 2
demonstrates that we may expect Y a few thousand Pa for
normal cells and only a few hundred Pa for the corresponding
tumor cells [139–142]. Generally, the stiffness decreases with
increasing aggressiveness and invasiveness of tumor cells.
In summary, the membrane stiffness Y of aggressive tumor
cells ranges from 200 to 800Pa, leading to resonant frequen-
cies between 10Hz and 10 kHz (see above), while normal cells
do not resonate or have less resonance in this frequency win-
dow. Furthermore, because of the typical microenvironment,
tumor cells are isolated and surrounded by extracellular fluid.
Such single cells are more susceptible to an incident AM-RF
and show the theoretically predicted resonance behavior. In
comparison, normal cells are connected to one another in a
tissue and show a different—presumably significantly lower
resonance behavior—at higher frequencies. The different
mechanical properties of tumor cells and tissues can increase
the therapeutic ratio of AM-RF if an appropriate modulation
frequency spectrum is selected; data suggest that lower fre-
quencies <1 kHz are more effective.
We hypothesize that a large number of ion channels
demodulate the AM-RF and transfer these low-frequency
oscillations (in time to the AM frequency) mechanically to
the membrane. Then, parts of the cell membranes or the
entire cells oscillate in resonance with considerable displace-
ments. In extreme cases of mechanical stress, the membrane
might rupture, creating a hole. Such a long-dated water
channel between the extracellular and intracellular space will
cause ion fluxes along the concentration gradient that pre-
dominantly increases the Ca2þ load in the cell, but might
also lead to other ion imbalances (Naþ, Cl-, Kþ and pH). Less
pronounced membrane vibrations at lower SAR levels might
cause depolarization of the membrane potential or directly
open ion channels by distortion of the voltage sensor or
gate. Likely, T-type VGCCs that have already been identified
open at low depolarization (of only 10 20mV) with conse-
quential calcium influx into the cell (see Table 1).
Table 2. Literature data of Young’s modulus for various cell lines comparing
normal tissue cells and associated tumor cells arranged according to invasive-
ness top down.
Cell type Reference Y [Pa]
Theoretical cell: Boal [135]




r¼ 0.49999 (near fluid) 600
Lung: Cross et al. [139]
“normal” 2100
NSCLC 540
Breast: Cross et al. [139]
“normal” 1930
Adenocarcinoma 500
Breast: Jonas et al. [140]
MCF-10A (benign) 478
MDA-MB-231 (invasive) 341
Colon: Jonas et al. [140]
SW480 (non-invasive) 466
Hacat (invasive) 384
Lung: Jonas et al. [140]
A431 (non-invasive) 374
A125 (invasive) 265










For the theoretical estimations, we used KV  107 Pa of red cells [135] and
the relationship for the Young’s modulus Y [Pa]¼ 3 	 (1 – 2r) 	 KV. The
Poisson’s ratio r for red cells is >1/3 and indicates decreasing stiffness
(increasing bending elasticity) if r approaches 1=2. Note r¼ 1/3 for solids and
r ¼ 1=2 for fluids.
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Due to these oscillations, we expect a variety of mem-
brane changes, especially on ion channels, when we examine
different levels of SAR and different frequencies. Further sys-
tematic investigations with different parameters of AM-RF-HT
are therefore worthwhile. In particular, we expect a strong
interdependence of membrane properties on temperature
and future experiments should examine these interactions.
Relevant changes in the membrane properties, e.g., decreas-
ing stiffness Y, are expected even at low temperature
increases to 38 or 39 C.
6. Discussion and prospects for oncologic
applications
Clinical and preclinical data suggest the existence of antipro-
liferative non-thermal effects (Sections 3 and 4), which can
damage tumor cells at lower temperatures (<42 C) with low
(1–2W/kg) to moderate (5–25W/kg) or high (300W/kg) SAR
levels. Because of E  SAR1/2 spreading of E is not as high
ranging from E 50 V/m (at 1W/kg) to E 200 V/m (at 25W/
kg) and up to E 800 V/m (at 300W/kg). Because the investi-
gated non-thermal effects are caused predominantly by the
E-field, measurable effects are already expectable at a low
SAR of 1W/kg under certain conditions.
A plethora of publications examined possible genotoxic
effects of mobile phones [143–147] applying the mobile-spe-
cific frequencies around 900MHz, 1800MHz or 1950MHz.
The investigators found several biological effects, in particu-
lar, DNA damages that they attributed to the functionality of
DNA as a fractal, i.e. broadband, antenna [148]. Yakymenko
et al. [149,150] identified oxygen species overproduction
reactive to mobile-specific EMF as a major correlate, and
described several possible mechanisms in their reviews.
Panagopoulos et al. [151] elaborated the concept that free
ions on both sides of the cell membrane can oscillate and
might cause membrane disorders. Interestingly, most of
these studies confirmed our educated guesses that modu-
lated and/or pulsed fields are more effective than non-modu-
lated sinusoidal MW, e.g., [143,144,146]. These researchers
confined themselves to the risks of mobile phones and did
not discuss possible therapeutic applications. Some of their
results concerning modulation/pulsation are nevertheless of
interest for therapeutic applications. Note that these frequen-
cies have only minor applicability for therapeutic purposes
because of their limited penetration depth.
Our overview is intended to show that non-thermal
effects exist in the RF range of 10 30MHz that can be
exploited for therapeutic purposes as a further development
of conventional hyperthermia. Microscopic hot spots, which
are often cited as an explanation for alleged non-thermal
effects, were discussed in detail and could largely be
excluded both in the clinical studies discussed and in the
preclinical experiments (Section 5.1). Instead, we presented
possible mechanisms at ion channels for non-thermal effects
of sinusoidal RF (Section 5.2). The data suggest that add-
itional AM with selected (tumor-specific) modulation frequen-
cies might enhance the antiproliferative effects of sinusoidal
RF (Sections 3.3 and 4.3). We presented membrane resonan-
ces as a possible explanation for such frequency-dependent
behavior and could correlate the observed modulation fre-
quencies (hertz to kilohertz) with elastic membrane proper-
ties that are characteristic for tumor cells (Section 5.3).
These novel model approaches give some insight into
possible mechanisms of non-thermal effects, but do not
claim to be validated models that can quantitatively describe
the experiments. The exact mechanisms and the dependen-
cies of non-thermal effects are still unresolved and require
much more data that cover broader ranges of SAR, tempera-
tures and modulation frequency spectra as treatment param-
eters. Until now, the data regarding non-thermal effects for
therapeutic purposes are not nearly comparable to the scope
of the data on WB-HT and cRF-HT.
In particular, there is a lack of comparative measurements
of RF ±AM in cells and experimental tumors in order to
quantitatively record the influence of AM and enable refine-
ment of the theoretical approaches. Interestingly, in the pre-
clinical investigations with the mEHT, the data on the AM
were incompletely documented and apparently, no system-
atic variation was performed (Section 4.1). Such comparative
experiments are urgently needed.
However, the available data together indicate that the
feasibility, tolerance and effectiveness of optimized AM-RF-
HT might be distinctly superior to cRF-HT. AM-RF at
27.12MHz (TheraBionic) refers to some frequency-dependent
non-thermal effects at very low SAR (<0.4–2W/kg) but is of
limited clinical effectiveness and requires long expos-
ition times.
The AM-RF-HT at 13.56MHz promises higher effectiveness
with a few sessions of one hour per week [23]. The existing
data on AM-RF-HT suggest that low AM frequencies less
than kilohertz might be more effective. At these low frequen-
cies, the resonance of whole cells might be explained by
forced oscillations of a variety of ion channels.
In preclinical studies, application of AM-RF-HT at 13.56MHz
(mEHT) alone at moderate clinically feasible SAR levels
(<20–30W/kg) and temperatures (<41–42 C) might achieve
an estimated cell kill of 30–50% in the target region, which is
not achieved by RF-HT at temperatures 42 C (see [69]).
Therefore, AM-RF-HT monotherapy at 13.56MHz is a debatable
option. For example, if we integrate 2–3 AM-RF-HT at
13.56MHz sessions per week up to a total of 20 sessions into
an adjuvant scheme, this procedure might be comparable to
20	 2Gy with respect to cytotoxicity, taking into account pre-
clinical data. Preclinical results confirmed in vivo that a series of
AM-RF-HT monotherapy sessions with 48h intervals (2–3 times
a week) might be effective [63]. This is a clear deviation from
the rules of cRF-HT, which requires a combination of RT and/or
chemotherapy.
Available RF heating technology is suitable for exposing
anatomical regions such as the brain, liver, lung, and major
parts of the abdomen or pelvis. However, we require high SAR
[W/kg] for temperatures >42 C [temperature increase (DT) ¼
4.5 C from 37.5 C to 42 C] in a target with perfusion w [ml/
100g/min] as given by the following easy relationship [152]:
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SAR ½W=kg
 ¼ ðDT=1:4Þ 	 w ½ml=100 g=min

Only for w< 10ml/100 g/min are SAR of 30W/kg suffi-
cient, which are achievable using the elaborated APA tech-
nique. The less expensive capacitive technology might
achieve 10–15W/kg in deep anatomical regions. Therefore,
only in low-perfused tumors or tissues with w< 5ml/100 g/
min capacitive systems can gain temperatures >42 C.
Considering the non-thermal effects outlined in this
review, we expect relevant cytotoxicity at moderate SAR and
lower temperatures <42 C significantly reducing the high
demands for cRF-HT listed in quality assurance reports [10].
There is evidence that a pure RF has non-thermal antiproli-
ferative effects [55], whereby an RF of 10MHz might have
advantages over 100MHz (see Section 5.1). Further, preclin-
ical and clinical studies strongly suggest that a suitable AM
can increase RF effectiveness. However, we do not know
exactly the optimal modulation frequencies, SAR, and tem-
peratures for clinical applications. Therefore, further system-
atic preclinical studies are required to complete the
fragmentary data on non-thermal effects.
For cRF-HT, only tumors with low perfusion <10ml/100 g/
min are accessible for SAR ¼ 30W/kg to achieve 42–43 C;
even tumors with perfusion up to 40ml/100 g/min would be
accessible for the same SAR if temperatures of 38 C would
be considered sufficient to ensure non-thermal antiprolifera-
tive effects in conjunction with a slight temperature increase
(see the equation above). Here, we regard temperature as a
co-variable. Consequently, the possible applications in oncol-
ogy would increase considerably. These applications include
AM-RF-HT monotherapy but especially in combination with
other therapy modalities. If the existence of non-thermal
antiproliferative effects can be further substantiated, we
believe a new field opens up for oncology.
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